Qumis | $2,200,000 | (Jan 22, 2025)
Zynap | $5,937,902 | (Jan 22, 2025)
Belfry | $12,000,000 | (Jan 22, 2025)
Certified by Founder
Lodge
Angitia Biopharmaceuticals
start up
United States
- Woodland Hills, CA
- 12/12/2024
- Series C
- $120,000,000
Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key unmet medical needs of serious musculoskeletal diseases. With the team’s experience and scientific expertise in new drug development, Angitia is dedicated to bringing innovative therapeutics to help patients in need.
- Industry Biotechnology Research
- Website https://www.angitiabio.com/
- LinkedIn https://www.linkedin.com/company/angitia-biopharmaceuticals/
Related People
Hua Zhu (David) KeFounder
United States -
Greater Los Angeles, California
Discovery and translational research professional, specifically in bone and renal diseases.
Gravity | $13,000,000 | (Jan 22, 2025)
LeapXpert | $20,000,000 | (Jan 22, 2025)
BPR Hub | $2,600,000 | (Jan 22, 2025)
NovoLINC | Undisclosed Amount | (Jan 22, 2025)
IntusCare | $11,500,000 | (Jan 21, 2025)
ecoplanet | $16,571,680 | (Jan 21, 2025)
Sereact | $25,894,660 | (Jan 21, 2025)
Fundment | $55,157,175 | (Jan 21, 2025)
Men In Blazers Media Network | $150,000,000 | (Jan 21, 2025)